Karin Bowen

4.0k citations

30 papers · 2.8k indexed · 3 hit papers · h-index 15

Impact in

Immunology and Allergy top 2%
- Allergic Rhinitis and Sensitization
Oncology top 2%
- PARP inhibition in cancer therapy

Papers in

Immunology and Allergy 5
- Allergic Rhinitis and Sensitization 5
Physiology 20
- Asthma and respiratory diseases 20

Co-authors: Gene Colice Michael Friedländer Anitra Fielding Judith Balmañà Bella Kaufman Susan M. Domchek Ronnie Shapira‐Frommer Georgeta Fried
Journals: Respiratory Research (6 papers)Journal of Clinical Oncology (3 papers)American Journal of Respiratory and Critical Care Medicine (3 papers)Annals of Oncology (2 papers)JAMA (1 paper)
Partner nations: United States United Kingdom Sweden

In The Last Decade

Karin Bowen

27 papers receiving 2.7k citations

Hit Papers

align trajectories log scale

Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials 2023 · 95 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2023 American Journal of Respiratory and Critical Care Medicine
2021 New England Journal of Medicine
2014 Journal of Clinical Oncology

Peers

Countries citing papers authored by Karin Bowen

Since Specialization

Citations

This map shows the geographic impact of Karin Bowen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karin Bowen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karin Bowen more than expected).

Fields of papers citing papers by Karin Bowen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karin Bowen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karin Bowen. The network helps show where Karin Bowen may publish in the future.

Co-authors

The 25 scholars most cited alongside Karin Bowen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Karin Bowen Line = papers co-authored together Karin Bowen links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Effect of budesonide/glycopyrronium/formoterol fumarate dihydrate on cardiopulmonary outcomes in COPD: rationale and design of the THARROS trial ERJ Open Research ·Fernando J. Martinez, John R. Hurst, MeiLan K. Han, David Price, Jinping Zheng, David D. Berg, Michel Pszczol, Mona Bafadhel, Carolyn S.P. Lam, Martin Fredriksson, Martín Cowie, Niki Arya, Karin Bowen, Alec Mushunje, Mehul Patel	2025	0
2	Step up to triple therapy versus switch to dual bronchodilator therapy in patients with COPD on an inhaled corticosteroid/long-acting β2-agonist: post-hoc analyses of KRONOS Respiratory Research ·Dave Singh, Mona Bafadhel, Niki Arya, Jonathan Marshall, Himanshu Parikh, Dobrawa Kisielewicz, Charlotta Movitz, Karin Bowen, Mehul Patel	2025	0
3	Benefits of budesonide/glycopyrronium/formoterol fumarate dihydrate on lung function and exacerbations of COPD: a post-hoc analysis of the KRONOS study by blood eosinophil level and exacerbation history Respiratory Research ·Shigeo Muro, Tomotaka Kawayama, Hisatoshi Sugiura, Munehiro Seki, Elizabeth A. Duncan, Karin Bowen, Jonathan Marshall, Ayman Megally, Mehul S. Patel	2024	1
4	Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies for Patients with COPD and Phenotypic Features of Asthma: A Pooled Post Hoc Analysis of KRONOS and ETHOS International Journal of COPD ·Shigeo Muro, Munehiro Seki, John R. Hurst, David Petullo, Jonathan Marshall, Karin Bowen, Patrick Darken, Elizabeth Duncan, Ayman Megally, Mehul S. Patel	2024	0
5	Effect of Triple Therapy on Cardiovascular and Severe Cardiopulmonary Events in Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis of a Randomized, Double-Blind, Phase 3 Clinical Trial (ETHOS) American Journal of Respiratory and Critical Care Medicine ·Dave Singh, Fernando J. Martínez, John R. Hurst, MeiLan K. Han, Chris P Gale, Martin Fredriksson, Dobrawa Kisielewicz, Alec Mushunje, Charlotta Movitz, N. Ojili, Himanshu Parikh, Niki Arya, Karin Bowen, Mehul S. Patel	2024	10
6	Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials American Journal of Respiratory and Critical Care Medicine ·Jonathan Corren, Andrew Menzies‐Gow, Geoffrey Chupp, Elliot Israel, Stephanie Korn, Bill Cook, Christopher S. Ambrose, Åsa Hellqvist, Stephanie L. Roseti, Néstor A. Molfino, Jean‐Pierre Llanos, Neil Martin, Karin Bowen, Janet M. Griffiths, Jane R. Parnes, Gene Colice Hit paper breakdown →	2023	95
7	Reply to Lipworth and Chan American Journal of Respiratory and Critical Care Medicine ·Christopher S. Ambrose, Elliot Israel, Karin Bowen, Jean‐Pierre Llanos, Neil Martin, Bill Cook, Åsa Hellqvist, Stephanie Korn, Andrew Menzies‐Gow, Stephanie L. Roseti, Néstor A. Molfino, Janet M. Griffiths, Jane R. Parnes	2023	1
8	Mortality risk reduction with budesonide/glycopyrrolate/formoterol fumarate versus fluticasone furoate/umeclidinium/vilanterol in COPD: a matching-adjusted indirect comparison based on ETHOS and IMPACT Current Medical Research and Opinion ·Daiana Stolz, Erik Hermansson, Mario Ouwens, Barinder Singh, Akanksha Sharma, Dan Jackson, Patrick Darken, Jonathan Marshall, Karin Bowen, Hana Müllerová, Bernardino Alcázar Navarrete, Richard Russell, MeiLan K. Han, Deniz Tansey-Dwyer	2023	8
9	Efficacy of tezepelumab in patients with low and high bronchodilator reversibility in PATHWAY Pneumologie ·Jonathan Corren, M C Liu, Karin Bowen, Kinga Sałapa, Gene Colice, J P Llanos-Ackert	2021	1
10	CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma Respiratory Research ·Claire Emson, Sarah Diver, Latifa Chachi, Ayman Megally, Cherrie L. Small, John Downie, Jane R. Parnes, Karin Bowen, Gene Colice, Christopher E. Brightling	2020	25
11	NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma Respiratory Research ·Andrew Menzies‐Gow, Gene Colice, Janet M. Griffiths, Gun Almqvist, Sandhia Ponnarambil, Primal Kaur, Gennaro Ruberto, Karin Bowen, Åsa Hellqvist, May Mo, Esther García Gil	2020	70
12	DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma Respiratory Research ·Andrew Menzies‐Gow, Sandhia Ponnarambil, John Downie, Karin Bowen, Åsa Hellqvist, Gene Colice	2020	45
13	SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma Respiratory Research ·Michael E. Wechsler, Gene Colice, Janet M. Griffiths, Gun Almqvist, Tor Skärby, Teresa Piechowiak, Primal Kaur, Karin Bowen, Åsa Hellqvist, May Mo, Esther García Gil	2020	60
14	Efficacy of tezepelumab in patients with low and high bronchodilator reversibility in PATHWAY Jonathan Corren, Mark C. Liu, Karin Bowen, Kinga Sałapa, Gene Colice, Jean-Pierre Llanos-Ackert	2020	1
15	Application of structured statistical analyses to identify a biomarker predictive of enhanced tralokinumab efficacy in phase III clinical trials for severe, uncontrolled asthma BMC Pulmonary Medicine ·Mattis Gottlow, David Svensson, Ilya Lipkovich, Monika Huhn, Karin Bowen, Peter Wessman, Gene Colice	2019	9
16	Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials The Lancet Respiratory Medicine ·Reynold A. Panettieri, Ulf Sjöbring, AnnaMaria Péterffy, Peter Wessman, Karin Bowen, Edward Piper, Gene Colice, Christopher E. Brightling	2018	177
17	Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma European Respiratory Journal ·William W. Busse, Guy Brusselle, Stephanie Korn, Piotr Kuna, A. Magnan, David Cohen, Karin Bowen, Teresa Piechowiak, Millie Wang, Gene Colice	2018	49
18	SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer Annals of Oncology ·J.C. Soria, András Fülöp, Carlos Dias Maciel, Jürgen R. Fischer, Gustavo Girotto, S. Lago, Egbert F. Smit, Gyula Ostoros, Wilfried Eberhardt, P. Lishkovska, Susan Lovick, G Mariani, Astrid McKeown, Elaine Kilgour, Paul D. Smith, Karin Bowen, Alexander Kohlmann, David Carlile, Pasi A. Jänne	2017	24
19	Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer JAMA ·Pasi A. Jänne, Michel M. van den Heuvel, Fabrice Barlési, Manuel Cobo, Julien Mazières, Lucio Crinò, С. В. Орлов, Fiona Blackhall, Juergen Wolf, Pilar Garrido, Artem Poltoratskiy, G Mariani, Dana Ghiorghiu, Elaine Kilgour, Paul D. Smith, Alexander Kohlmann, David Carlile, David Lawrence, Karin Bowen, Johan Vansteenkiste	2017	249
20	Selumetinib in combination with docetaxel as second-line treatment for patients with KRAS-mutant advanced NSCLC: Results from the phase III SELECT-1 trial Annals of Oncology ·Pasi A. Jänne, Michel M. van den Heuvel, Fabrice Barlési, M. Cobo, Julien Mazières, Lucio Crinò, Sergey Orlov, Fiona Blackhall, Jennifer Moriatis Wolf, Pilar Garrido, Artem Poltoratskiy, G Mariani, Dana Ghiorghiu, Elaine Kilgour, Paul D. Smith, Alexander Kohlmann, David Carlile, David Lawrence, Karin Bowen, Johan Vansteenkiste	2016	10

About Karin Bowen

Karin Bowen is a scholar working on Immunology and Allergy, Physiology, Pulmonary and Respiratory Medicine, Dermatology and Oncology, having authored 30 papers that have together received 2.8k indexed citations. Recurring topics across this work include Asthma and respiratory diseases (20 papers), Respiratory and Cough-Related Research (8 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (7 papers), Respiratory Support and Mechanisms (6 papers), Allergic Rhinitis and Sensitization (5 papers), Inhalation and Respiratory Drug Delivery (5 papers), IL-33, ST2, and ILC Pathways (4 papers) and Dermatology and Skin Diseases (4 papers). The work is most often cited by research in Immunology and Allergy (338 citations), Oncology (1.3k citations), Reproductive Medicine (334 citations), Physiology (1.0k citations) and Pulmonary and Respiratory Medicine (942 citations). Karin Bowen has collaborated with scholars based in United States, United Kingdom and Sweden. Frequent co-authors include Gene Colice, Michael Friedländer, Anitra Fielding, Judith Balmañà, Bella Kaufman, Susan M. Domchek, Ronnie Shapira‐Frommer, Georgeta Fried, Gillian Mitchell and M. William Audeh. Their work appears in journals such as Respiratory Research, Journal of Clinical Oncology, American Journal of Respiratory and Critical Care Medicine, Annals of Oncology and JAMA.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact